Stock GWPH GW PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

GW Pharmaceuticals plc

Equities

GWPH

US36197T1034

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about GW Pharmaceuticals plc

Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav RE
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug MT
Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures MT
Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex CI
Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy MT
Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase MT
Palla Pharma : Names New CEO; Shares Soar 18% MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index CI
Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index CI
Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc. CI
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index CI
Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Jazz Pharmaceuticals : Closes $1.5 Billion Notes Offering MT
GW Pharmaceuticals : Shareholders' Green-light $7.2 Billion Sale To Jazz Pharmaceuticals MT
GW Pharmaceuticals : Shareholders OK Takeover by Jazz Pharmaceuticals MT
Jazz Pharmaceuticals : Pharma Prices $1.5 Billion Senior Secured Notes Offering MT
Jazz Pharmaceuticals : Subsidiary Discloses Proposed Private Offering of Senior Notes MT
GW Pharmaceuticals plc Receives European Commission Approval for EPIDYOLEX® (Cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex CI
Insider Trends: 90-Days of Insider Buying at GW Pharmaceuticals Eased Back with Share Disposition MT
Takeda Pharmaceutical : buys epilepsy treatment rights from Ovid for up to $856 million RE
GW Pharmaceuticals : Receives Positive Opinion for Epidyolex Application in EU MT
GW Pharmaceuticals plc Receives Positive CHMP Opinion for Epidyolex (Cannabidiol) for Use as Treatment of Seizures Associated with Tuberous Sclerosis Complex CI
GW Pharmaceuticals : Reports Wider Q4 Losses, Higher Revenue MT

Chart GW Pharmaceuticals plc

Chart GW Pharmaceuticals plc
More charts

Company Profile

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GWPH Stock
  4. News GW Pharmaceuticals plc
  5. GW Pharmaceuticals : Shareholders' Green-light $7.2 Billion Sale To Jazz Pharmaceuticals